Clinical Trial Update: Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating homologous recombination repair status as a biomarker of response in locally recurrent/metastatic triple-negative breast cancer treated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Locally Recurrent Metastatic Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Locally Recurrent/Metastatic Triple Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-02-09